Screener / SEC EDGAR /CIK 0001723128 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Amneal Pharmaceuticals, Inc. AMRX

Compare with peers Embed
FY2025 at a glance

Sales up 8.0%, free cash flow up to $269.9M

XBRL, from each 10-K
RevenueStatements
$3.0B from $2.8B in FY2024
FY2016FY2025
Net incomeStatements
$72.1M from -$116.9M in FY2024
FY2016FY2025
Free cash flowStatements
$269.9M from $243.2M in FY2024
FY2016FY2025
EPS (diluted)Statements
$0.22 from $-0.38 in FY2024
FY2016FY2025
Operating marginStatements
13.1% from 8.9% in FY2024
FY2016FY2025
Total debtStatements
$2.6B from $2.4B in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (44)
EPS (ttm)
0.40
Sales (ttm)
3.2B
Net income (ttm)
133.3M
Sales growth
+8.0%
EPS growth
-
Sales Q/Q
+10.0%
Free cash flow
88.2M
Gross margin
40.2%
Oper. margin
15.0%
Net margin
4.2%
FCF margin
2.8%
ROA
2.5%
R&D / sales
6.2%
Dividend
-
Debt/Eq
5.53
Curr. ratio
1.87
Cash
157.4M
Op. cash flow (ttm)
180.6M
EBITDA
451.4M
EBITDA margin
15.0%
Net debt
2.8B
Quick ratio
1.33
Interest cover
1.99
ROIC
10.4%
FCF after stock pay
238.0M
Debt / FCF (years)
10.89
Goodwill / assets
16.2%
Oper. margin low 5y
-4.3%
Tax rate
8.1%
Stock pay / sales
1.1%
Shares out.
348.4M
Shares Y/Y
+5.1%
Book / share
1.52
Cash / share
0.45
Sales / share
9.17
Asset turnover
0.61
Inventory turns
3.14
Days sales out.
90
Sales 3Y CAGR
+10.9%
Sales 5Y CAGR
+8.7%
EPS 5Y CAGR
-18.5%
Employees
8,500
Sales / employee
376K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 3.0B +12.8% a year Net income 72.1M
FY2016 revenue 1.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001723128-19-000028 FY2016 net income 0 · NetIncomeLoss, 0001723128-19-000028 1.0B FY2016 FY2017 revenue 1.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-20-008179 FY2017 net income 0 · NetIncomeLoss, 0001564590-20-008179 1.0B FY2017 FY2018 revenue 1.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001723128-21-000013 FY2018 net income -19.7M · NetIncomeLoss, 0001723128-21-000013 1.7B FY2018 FY2019 revenue 1.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001723128-22-000006 FY2019 net income -603.6M · NetIncomeLoss, 0001723128-22-000006 1.6B FY2019 FY2020 revenue 2.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001723128-23-000009 FY2020 net income 67.8M · NetIncomeLoss, 0001723128-23-000009 2.0B FY2020 FY2021 revenue 2.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001723128-24-000014 FY2021 net income 13.2M · NetIncomeLoss, 0001723128-24-000014 2.1B FY2021 FY2022 revenue 2.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001723128-25-000012 FY2022 net income -270.6M · NetIncomeLoss, 0001723128-24-000014 2.2B FY2022 FY2023 revenue 2.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001723128-26-000011 FY2023 net income -84.0M · NetIncomeLoss, 0001723128-26-000011 2.4B FY2023 FY2024 revenue 2.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001723128-26-000011 FY2024 net income -116.9M · NetIncomeLoss, 0001723128-26-000011 2.8B FY2024 FY2025 revenue 3.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001723128-26-000011 FY2025 net income 72.1M · NetIncomeLoss, 0001723128-26-000011 3.0B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2016 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share -18.5% a year FY2020 $0.61 to FY2025 $0.22, 5 years
Free cash flow per share -6.3% a year FY2018 $1.31 to FY2025 $0.83, 7 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.22-$0.22$0.83
Dec 31, 2024 -$0.38-$0.35$0.79
Dec 31, 2023 -$0.48$0.11$1.72
Dec 31, 2022 -$0.86$1.98$0.12
Dec 31, 2021 $0.07$2.37$1.28
Dec 31, 2020 $0.61$2.04$2.17
Dec 31, 2019 -$2.74$1.76-$0.34
Dec 31, 2018 -$0.16$3.97$1.31
Dec 31, 2017 ---
Dec 31, 2016 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.9B
  • − All liabilities (total assets less equity) $3.7B
  • = Net current asset value -$1.8B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $70.8M
  • − Goodwill $595.5M
  • − Other intangible assets $563.5M
  • = Tangible book value -$1.2B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result. This company does not tag total liabilities, so total assets less equity is used (it includes any non-controlling interest).

AMRX against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+8.0%93rd of 155 · median +10.5%
Net margin
-4.1%15.3%
4.2%84th of 154 · median 6.8%
Return on equity
-5.2%18.5%
25.1%21st of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
2.8%107th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
5.53107th of 108 · median 0.69
AMRX and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
AMRX Amneal Pharmaceuticals, Inc.$3.2B +8.0%40.2%4.2%25.1%2.8%5.53
WST West Pharmaceutical Services$3.4B +6.3%37.6%18.8%21.5%13.3%0.07
SGRY Surgery Partners, Inc.$3.4B +6.2%--2.6%-5.2%6.0%1.84
PODD Insulet Corporation$3.2B +30.7%71.9%13.4%27.1%8.2%0.61
UTHR UNITED THERAPEUTICS Corp$3.2B +10.6%86.3%38.6%19.6%27.2%-
GMED Globus Medical Inc$3.1B +16.7%69.1%17.8%11.6%24.4%-
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by segment

From $2.1B of sales to $13.2M of profit FY2021

  • AvKARE $349.0M
  • Specialty $378.3M
  • Generics $1.4B
Revenue to Gross profit: $769.0MRevenue to Cost of revenue: $1.3BGross profit to Operating profit: $152.7MGross profit to Operating expenses: $616.3MOperating profit to Net profit: $13.2MOperating profit to Tax & other: $139.6MOperating expenses to R&D: $201.8MOperating expenses to Sales, admin & other: $414.4M Revenue: $2.1B REVENUE $2.1B +5% Y/Y Gross profit: $769.0M · 37% margin GROSS PROFIT $769.0M 37% margin · +22% Y/Y Cost of revenue: $1.3B · 63% of revenue COST OF REVENUE $1.3B 63% of revenue Operating profit: $152.7M · 7% margin OPERATING PROFIT $152.7M 7% margin · +68% Y/Y Operating expenses: $616.3M · 29% of revenue OPERATING EXPENSES $616.3M 29% of revenue Net profit: $13.2M · 1% margin NET PROFIT $13.2M 1% margin · −81% Y/Y Tax & other: $139.6M · 7% of revenue TAX & OTHER $139.6M 7% of revenue R&D: $201.8M · 10% of revenue R&D $201.8M 10% of revenue Sales, admin & other: $414.4M · 20% of revenue SALES, ADMIN & OTHER $414.4M 20% of revenue

From $3.0B of sales to $72.1M of profit FY2025

  • Affordable Medicines $1.7B
  • AvKARE $744.7M
  • Specialty $528.5M
Revenue to Gross profit: $1.1BRevenue to Cost of revenue: $1.9BGross profit to Operating profit: $394.1MGross profit to Operating expenses: $719.2MOperating profit to Net profit: $72.1MOperating profit to Tax & other: $322.0MOperating expenses to R&D: $186.2MOperating expenses to SG&A: $533.0M Revenue: $3.0B REVENUE $3.0B +8% Y/Y Gross profit: $1.1B · 37% margin GROSS PROFIT $1.1B 37% margin · +9% Y/Y Cost of revenue: $1.9B · 63% of revenue COST OF REVENUE $1.9B 63% of revenue Operating profit: $394.1M · 13% margin OPERATING PROFIT $394.1M 13% margin · +58% Y/Y Operating expenses: $719.2M · 24% of revenue OPERATING EXPENSES $719.2M 24% of revenue Net profit: $72.1M · 2% margin NET PROFIT $72.1M 2% margin Tax & other: $322.0M · 11% of revenue TAX & OTHER $322.0M 11% of revenue R&D: $186.2M · 6% of revenue R&D $186.2M 6% of revenue SG&A: $533.0M · 18% of revenue SG&A $533.0M 18% of revenue

Where each $100 of sales went

FY2021
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Profitability

  • Net margin below the peer median
    4.2% vs 6.8%
  • Gross margin up over 5 years
    31.5% → 36.9%
  • Return on equity above 15%
    25.1%
  • A profit in 3 of 10 years
Net margin, FY2016 to FY2025: 0.0% to 2.4%

Balance sheet

  • Interest covered less than 5 times
    Operating income is 2.0× interest expense
  • Debt larger than equity
    Debt / equity 5.53 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 1.87
  • Net debt over 3 years of free cash flow
    $2.8B net debt, 31.5 years
Debt / equity at each year end, FY2016 to FY2025: 5.25 to 122.35

Cash and shareholders

  • Free cash flow positive in 8 of 10 years
    $269.9M last year
  • Share count up over 5 years
    +118.1%
  • Cash from operations above net income
    $340.0M vs $72.1M
Free cash flow, FY2016 to FY2025: -7.7M to 269.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$- of principal due

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

AMRX's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue3.0B
FY2016: 1.0BFY2017: 1.0BFY2018: 1.7BFY2019: 1.6BFY2020: 2.0BFY2021: 2.1BFY2022: 2.2BFY2023: 2.4BFY2024: 2.8BFY2025: 3.0B FY2017FY2019FY2021FY2023FY2025
Net income72.1M
FY2016: 0FY2017: 0FY2018: -19.7MFY2019: -603.6MFY2020: 67.8MFY2021: 13.2MFY2022: -270.6MFY2023: -84.0MFY2024: -116.9MFY2025: 72.1M FY2017FY2019FY2021FY2023FY2025
Free cash flow269.9M
FY2016: -7.7MFY2017: 139.4MFY2018: 167.1MFY2019: -45.5MFY2020: 322.6MFY2021: 194.1MFY2022: 18.7MFY2023: 302.4MFY2024: 243.2MFY2025: 269.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay238.0M
FY2016: -7.7MFY2017: 139.4MFY2018: -455KFY2019: -67.2MFY2020: 301.8MFY2021: 165.7MFY2022: -13.2MFY2023: 275.5MFY2024: 215.4MFY2025: 238.0M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)0.22
FY2016: -FY2017: -FY2018: -0.16FY2019: -2.74FY2020: 0.61FY2021: 0.07FY2022: -0.86FY2023: -0.48FY2024: -0.38FY2025: 0.22 FY2017FY2019FY2021FY2023FY2025
Diluted shares324.8M
FY2016: -FY2017: -FY2018: 127.3MFY2019: 132.1MFY2020: 148.9MFY2021: 151.8MFY2022: 150.9MFY2023: 176.1MFY2024: 309.0MFY2025: 324.8M FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
Affordable Medicines 1.7B57.8% +3.6%
AvKARE 744.7M24.7% +12.3%
Specialty 528.5M17.5% +18.6%

10-K 0001723128-26-000011, segment and revenue notes (XBRL).

Revenue by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Affordable Medicines-1.4B1.5B1.7B1.7B
AvKARE349.0M406.1M531.7M662.9M744.7M
Specialty378.3M374.1M390.5M445.7M528.5M
Generics1.4B1.4B1.5B--

Operating income by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Affordable Medicines-224.2M276.2M270.1M380.8M
Specialty56.4M72.6M65.3M113.6M116.0M
Av KARE6.8M3.3M31.5M42.9M83.6M
Generics281.5M224.2M276.2M--
Corporate and other-192.0M-395.0M-168.6M-177.3M-186.3M

Revenue and operating income by business segment, as each 10-K reports them in its segment note (XBRL). Each year comes from the newest 10-K that reports it, so a year the company later recast shows the recast number; click a number to open that 10-K. Segments changed: FY2021, FY2022, FY2023 are in italics, as first reported under the earlier segments, so they are not comparable with the later years. Rows without a number were not reported as a separate segment that year. "Corporate and other" and "All other" are the 10-K's own lines for what is outside the segments.

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue1.0B1.0B1.7B1.6B2.0B2.1B2.2B2.4B2.8B3.0B
Cost of revenue420.8M507.5M938.8M1.1B1.3B1.3B1.4B1.6B1.8B1.9B
Gross profit597.5M526.2M716.4M353.0M628.4M769.0M784.7M820.6M1.0B1.1B
R&D179.0M171.4M194.2M188.0M179.9M201.8M195.7M163.9M190.7M186.2M
SG&A118.8M109.0M227.8M289.6M326.7M365.5M399.7M429.7M476.4M526.8M
Operating income284.9M245.1M-19.7M-248.7M91.2M152.7M-94.9M204.4M249.3M394.1M
Interest expense50.6M65.1M131.5M158.6M130.2M121.7M142.7M192.8M263.5M197.8M
Pretax income214.8M171.3M-202.7M-220.2M-35.8M31.4M-248.1M-40.3M-55.0M139.2M
Income tax5.4M2.0M-1.4M383.3M-104.4M11.2M6.7M8.5M18.9M11.3M
Net income00-19.7M-603.6M67.8M13.2M-270.6M-84.0M-116.9M72.1M
EPS (diluted)---0.16-2.740.610.07-0.86-0.48-0.380.22
Diluted shares--127.3M132.1M148.9M151.8M150.9M176.1M309.0M324.8M
Depreciation & amortization29.3M42.0M64.4M63.3M60.4M60.7M68.1M66.2M62.6M57.3M
EBITDA314.2M287.1M44.7M-185.4M151.6M213.4M-26.8M270.6M311.9M451.4M
Gross margin58.7%50.9%43.1%21.7%31.5%36.7%35.5%34.3%36.5%36.9%
Operating margin28.0%23.7%-1.2%-15.3%4.6%7.3%-4.3%8.5%8.9%13.1%
Net margin0.0%0.0%-1.2%-37.1%3.4%0.6%-12.2%-3.5%-4.2%2.4%
Revenue growth-+1.5%+60.9%-2.2%+22.5%+5.1%+5.7%+8.2%+16.7%+8.0%
EPS growth------88.5%to a loss---

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow115.1M234.2M250.2M1.7M379.0M241.8M65.1M345.6M295.1M340.0M
Capital spending122.8M94.8M83.1M47.2M56.4M47.7M46.4M43.2M51.9M70.1M
Free cash flow-7.7M139.4M167.1M-45.5M322.6M194.1M18.7M302.4M243.2M269.9M
Stock-based pay (added back)00167.6M21.7M20.8M28.4M31.8M26.8M27.8M32.0M
Free cash flow after stock pay-7.7M139.4M-455K-67.2M301.8M165.7M-13.2M275.5M215.4M238.0M
Dividends paid200.6M375.3M183.0M00-----
Acquisitions00324.6M0251.4M146.5M84.7M00-
Debt raised-----00217.7M02.7B
Investing cash flow-124.6M-98.6M-396.4M-19.6M-317.5M-194.2M-174.3M-69.2M-63.0M-112.3M
Financing cash flow-19.5M-95.0M287.7M-45.8M131.8M-138.1M-106.6M-212.6M-211.8M-31.5M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)00167.6M21.7M20.8M28.4M31.8M26.8M27.8M32.0M
Stock-based pay / revenue0.0%0.0%10.1%1.3%1.0%1.4%1.4%1.1%1.0%1.1%
Operating lease cash paid---20.1M18.8M15.0M16.2M16.0M17.1M17.1M
Finance lease principal paid---2.3M2.8M3.2M3.5M3.6M3.3M3.4M
Right-of-use assets--85.0M69.9M58.7M60.4M56.1M43.3M42.4M54.0M
Operating lease liabilities--97.6M73.0M62.5M64.0M59.2M48.9M47.0M58.8M
Finance lease liabilities--64.0M62.5M65.5M63.4M64.3M61.0M60.1M58.4M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AMRX/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.